Qiagen presents a patent complaint against biomérieux to protect Quantiferon technology

Paris (DPA -Afx) – Qiagen NV (QGen) announced that it has filed a complaint against Biomrieux S for violation of patents, reinforcing its commitment to protect scientific advances behind its patented quantiferon technology.

The complaint, presented to the local division of the Court of First Instance of the Unified Patent Court in Düsseldorf, Germany, refers to the European Patent EP 2 276 883 B2.

The patent, among several which protects the quantiferon technology, covers significant innovations in the quantiferon-tb Gold Plus, which is used throughout the world for the detection of tuberculosis (TB).

Copyright (c) 2025 rttnews.com. All rights reserved

Copyright RTT News/DPA-AFX